Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Assertio Holdings, Inc.(ASRT) Investors of a Class Action Lawsuit and Upcoming Deadline

ASRT

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.

Levi & Korsinsky, LLP (PRNewsfoto/Levi & Korsinsky, LLP)

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Assertio Holdings investors who were adversely affected by alleged securities fraud between March 29, 2023 and November 8, 2023. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=65141&wire=4

ASRT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company's reliance on Indocin products to boost its net income was unsustainable given the risk of generic competition; (ii) Assertio's acquisition of Spectrum Pharmaceuticals, Inc. and Spectrum's injection asset, Rolvedon, was less valuable than Assertio had represented to investors; (iii) accordingly, Assertio had overstated the positive impact the sale of Indocin products and the acquisition were likely to have on the Company's profitability; and (iv) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

WHAT'S NEXT? If you suffered a loss in Assertio Holdings during the relevant time frame, you have until March 5, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-levi--korsinsky-notifies-assertio-holdings-incasrt-investors-of-a-class-action-lawsuit-and-upcoming-deadline-302047414.html

SOURCE Levi & Korsinsky, LLP

Tags: